{"id":"NCT00102063","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Aripiprazole in Adolescents With Schizophrenia","officialTitle":"Aripiprazole in Adolescents With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-07","primaryCompletion":"2006-08","completion":"2006-08","firstPosted":"2005-01-20","resultsPosted":"2012-08-01","lastUpdate":"2012-08-10"},"enrollment":302,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Aripiprazole tablet, 10 mg","otherNames":["OPC-14597"]},{"type":"DRUG","name":"Aripiprazole tablet, 30 mg","otherNames":["OPC-14597"]},{"type":"DRUG","name":"Placebo tablet","otherNames":[]}],"arms":[{"label":"Aripiprazole 10 mg/day Group","type":"ACTIVE_COMPARATOR"},{"label":"Aripiprazole 30 mg/day Group","type":"ACTIVE_COMPARATOR"},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.","primaryOutcome":{"measure":"Change in Positive and Negative Syndrome Scale (PANSS) Total Score","timeFrame":"Baseline and Day 42","effectByArm":[{"arm":"Aripiprazole 10 mg/Day Group","deltaMin":-26.7,"sd":1.9},{"arm":"Aripiprazole 30 mg/Day Group","deltaMin":-28.6,"sd":0.9},{"arm":"Placebo Group","deltaMin":-21.2,"sd":1.9}],"pValues":[{"comp":"OG000 vs OG002","p":"0.05"},{"comp":"OG001 vs OG002","p":"0.007"}]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":55,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["23800482","20166794","18765484"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":100},"commonTop":["Extrapyramidal disorder","Somnolence","Headache","Insomnia","Nausea"]}}